Search

Your search keyword '"NTRK-Fusions"' showing total 2 results
Start Over Descriptor "NTRK-Fusions" Topic mismatch repair deficiency
2 results on '"NTRK-Fusions"'

1. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies

Author

Stefania Gori, Carmine Pinto, Antonio Russo, Rita Chiari, Laura Cortesi, Antonio Marchetti, Umberto Malapelle, Romano Danesi, Ettore Capoluongo, Nicola Silvestris, Dario Sangiolo, Bruno Vincenzi, Marzia Del Re, Giovanni Tallini, Pierosandro Tagliaferri, Saverio Cinieri, Giordano D. Beretta, Ada Maria Florena, Nicola Normanno, Gabriella Fontanini, Lorena Incorvaia, Russo A., Incorvaia L., Malapelle U., Del Re M., Capoluongo E., Vincenzi B., Chiari R., Cortesi L., Danesi R., Florena A.M., Fontanini G., Gori S., Marchetti A., Normanno N., Pinto C., Sangiolo D., Silvestris N., Tagliaferri P., Tallini G., Cinieri S., Beretta G.D., Russo, A., Incorvaia, L., Malapelle, U., Del Re, M., Capoluongo, E., Vincenzi, B., Chiari, R., Cortesi, L., Danesi, R., Florena, A. M., Fontanini, G., Gori, S., Marchetti, A., Normanno, N., Pinto, C., Sangiolo, D., Silvestris, N., Tagliaferri, P., Tallini, G., Cinieri, S., and Beretta, G. D.

Subjects
Societies, Scientific, Genomic profiling, Druggability, NTRK-Fusions, Medical Oncology, Neoplasms, Medicine, Humans, Agnostic biomarkers, Precision Medicine, Histology-agnostic, Tumor histology, business.industry, Agnostic drugs, Homologous recombination deficiency, Microsatellite instability, Mismatch repair deficiency, Precision oncology, Italy, Scientific, Hematology, Precision medicine, Data science, Oncology, Economic sustainability, Agnostic biomarker, Position paper, Neoplasm, Identification (biology), Personalized medicine, Agnostic drug, NTRK-Fusion, business, Societies, Human
Abstract

The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of "mutational oncology", presents a great potential to change the oncologic therapeutic scenario, but also some critical aspects need to be underlined. A process governance is mandatory to ensure the genomic testing accuracy and homogeneity, the economic sustainability, and the regulatory issues, ultimately granting the possibility of translating this model in the "real world". In this position paper, based on experts' opinion, the AIOM-SIAPEC-IAP-SIBIOC-SIF Italian Scientific Societies revised the new agnostic biomarkers, the diagnostic technologies available, the current availability of agnostic drugs and their present indication.

Published
2021

2. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies.

Author

Russo, Antonio, Incorvaia, Lorena, Malapelle, Umberto, Del Re, Marzia, Capoluongo, Ettore, Vincenzi, Bruno, Chiari, Rita, Cortesi, Laura, Danesi, Romano, Florena, Ada Maria, Fontanini, Gabriella, Gori, Stefania, Marchetti, Antonio, Normanno, Nicola, Pinto, Carmine, Sangiolo, Dario, Silvestris, Nicola, Tagliaferri, Pierosandro, Tallini, Giovanni, and Cinieri, Saverio

Subjects
*DRUG accessibility, *SUSTAINABLE development, *INDIVIDUALIZED medicine, *HISTOLOGY, *TUMORS
Abstract

[Display omitted] • Agnostic markers represent the novel frontier of precision medicine. • The first agnostic drugs have been approved regardless of tumor histology. • This model presents a great potential to change the oncological therapeutic scenario. • Despite the clinical opportunity, critical aspects are emerging. • A governance is mandatory to ensure genomic testing homogeneity and sustainability. The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of "mutational oncology", presents a great potential to change the oncologic therapeutic scenario, but also some critical aspects need to be underlined. A process governance is mandatory to ensure the genomic testing accuracy and homogeneity, the economic sustainability, and the regulatory issues, ultimately granting the possibility of translating this model in the "real world". In this position paper, based on experts' opinion, the AIOM–SIAPEC-IAP–SIBIOC–SIF Italian Scientific Societies revised the new agnostic biomarkers, the diagnostic technologies available, the current availability of agnostic drugs and their present indication. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results